Kokunai I, Shimano T, Sekimoto K, Takeda T, Kobayashi T, Yayoi E, Yamamoto A, Mori T
J Clin Lab Immunol. 1986 Dec;21(4):169-71.
We examined whether OK-432, a streptococcal preparation, could induce tumor necrosis factor in cancer patients. OK-432 was administered at a dose of 100 KE intratumorally to 4 advanced gastric cancer patients and 10KE intracavitary to 8 patients with malignant pleuroperitoneal effusion. The cytostatic activity of the sera and malignant effusions was assayed by the growth inhibition of L929 cells. OK-432 induced significant cytostatic activity in the sera and malignant effusions. The activity was partially neutralized by the monoclonal antibody against human recombinant tumor necrosis factor. These data suggest that OK-432 induces tumor necrosis factor in the sera and malignant effusions of cancer patients.
我们研究了链球菌制剂OK-432是否能在癌症患者体内诱导肿瘤坏死因子。对4例晚期胃癌患者瘤内注射100KE剂量的OK-432，对8例恶性胸膜腔积液患者腔内注射10KE剂量的OK-432。通过L929细胞生长抑制试验检测血清和恶性积液的细胞抑制活性。OK-432在血清和恶性积液中诱导出显著的细胞抑制活性。该活性部分被抗人重组肿瘤坏死因子单克隆抗体中和。这些数据表明OK-432能在癌症患者的血清和恶性积液中诱导肿瘤坏死因子。
